



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

16 Feb 2016 (#5)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- NIH Policy on Informed Consent for Human Fetal Tissue Research ([NOT-OD-16-033](#))
- Impact of Grant Application Form Update (FORMS-D) on Late and Continuous Submission Applications ([NOT-OD-16-064](#))
- Registration Now Open for the Spring & Fall 2016 NIH Regional Seminars on Program Funding & Grants Administration ([NOT-OD-16-065](#))
- Notice of Correction to the Award Budget for PAR-16-084 "Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)" ([NOT-CA-16-022](#))
- PAR-12-200 NIOSH Small Research Grant Program (R03): Musculoskeletal Health Research Priorities ([NOT-OH-16-011](#))
- PAR-12-252 NIOSH Exploratory/Developmental Research Grant Program (R21): Musculoskeletal Health Research Priorities ([NOT-OH-16-012](#))
- PAR-13-129 Occupational Safety and Health Research (R01): Musculoskeletal Health Research Priorities ([NOT-OH-16-013](#))

1. Assessing Human Placental Development and Function Using Existing Data

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** [\(RFA-HD-17-004\)](#) **Type:** R01
[\(RFA-HD-17-005\)](#) R21

Application Due Date: April 6, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This funding opportunity announcement (FOA) is for the evaluation of human placental development and function across pregnancy through the application of assessment technologies to existing data.

Budget: R01: NICHD intends to commit \$2,000,000 in FY 2017 to fund 1-3 awards. Application budgets are limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21:** NICHD intends to commit \$500,000 in FY 2017 to fund 1-2 awards. The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

2. T4 Translation Research Capacity Building Initiative in Low Income Countries (TREIN)

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** [\(RFA-HL-17-003\)](#) **Type:** U24

Application Due Date: June 15, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to build in-country capacity through the creation of a trans-disciplinary investigative team to guide the conduct of late-stage translation phase 4 research (T4TR) in low income countries (as defined by The World Bank) through skills development programming, needs assessment, and capacity building. Studies will be required to address chronic non-communicable heart, lung, blood and sleep diseases and disorders in low income countries.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NHLBI intends to commit up to total costs of \$750,000 per year for Fiscal years 2017 through 2020 to fund up to five awards. Application budgets may not exceed \$138,000 direct costs per year. The maximum project period is 4 years.

3. Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** [\(RFA-RM-16-002\)](#) **Type:** OT1

Application Due Date: Applications are accepted March 11, 2016, and May 16, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite pre-applications from applicants who have an interest in ultimately submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)" (RFA-RM-16-003). The OT1 SPARC pre-application is the required first step in the application process for the companion OT2 FOA (RFA-RM-16-003). **Potential applicants should read both FOAs.** Applicants whose OT1 pre-applications are found to be meritorious and programmatically relevant will be invited to submit a full application to the OT2 "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System" FOA (RFA-RM-16-003). There will be substantial interaction with NIH Program Staff leading to the development of programmatic and budget elements for an acceptable OT2 application. OT2 applications must include a copy of the Invitation to Submit from the SPARC program as a requirement for submission. The Invitation to Submit an OT2 application is not an indication of any award. No Other Transaction awards will be made under this FOA. This NIH Funding Opportunity Announcement (FOA) solicits pre-applications to develop new and/or enhance existing tools and technologies to be used to elucidate the neurobiology and neurophysiology underlying autonomic control of organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These two-year projects will facilitate technology development for neural mapping activities through the NIH SPARC Common Fund program.

Budget: No awards will be made under this OT1 FOA. The timeline for OT1 applications received by the designated due dates will allow consideration of a possible OT2 application for FY16 funds under the companion announcement FOA RFA-RM-16-003.

4. Limited Competition - Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** [\(RFA-RM-16-003\)](#) **Type:** OT2

Application Due Date: New and Resubmission applications are accepted on the date specified in the Invitation to Submit after successful competition of the corresponding OT1 application (See RFA-RM-16-002) and must be submitted by 5:00 PM local time of the applicant organization. Applications submitted after 5:00 PM local time of the applicant organization will automatically roll forward to the next due date, except for the last due date, for which no late applications will be accepted. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications (via limited competition) for SPARC Technologies to Understand the Control of Organ Function by the Peripheral Nervous System. These projects will develop new and/or enhance existing tools and technologies to be used to elucidate the neurobiology and neurophysiology underlying autonomic control of organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These two-year projects will facilitate technology development for neural mapping activities through the NIH Common Fund SPARC program. Applications are only accepted after successful competition of the corresponding OT1 pre-application (See RFA-RM-16-002) and invitation to the applicant to submit the OT2 application.

Budget: NIH intends to fund an estimate of 10-15 awards through this FOA. NIH estimates funding up to 5 awards in fiscal year 2016, corresponding to a total of up to approximately \$4M. An additional 5-10 awards are estimated for funding in future years. Future year amounts will depend on annual appropriations and programmatic needs for additional SPARC research. Application budgets are not limited but need to reflect the actual needs of the proposed project. Awards are expected to range between \$250,000 to \$300,000 direct costs per year. The project period is limited to 2 years with the opportunity for supplemental funding as described above.

5. Accelerating Research on Intervertebral Disc (ARID)

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** [\(PA-16-096\)](#) **Type:** R21
[\(PA-16-097\)](#) R01

Application Due Date: Standard dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage the submission of grant applications proposing studies on basic biology of the intervertebral disc. The NIAMS invites investigators from all areas of cell biology, bioengineering, and orthopaedic research to consider individual or collaborative efforts to address these needs. Applications that accelerate an understanding of basic research on the intervertebral disc and/or develop new directions on the factors that lead to disc degeneration are particularly encouraged.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. Basic Biopsychosocial Mechanisms and Processes in the Management of Chronic Conditions

Letter of Intent due date: Usually 30 days prior to the application due date

Hyperlink: [\(PAR-16-095\)](#)

Type: R21

Application Due Date: December 6, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This FOA seeks to stimulate basic inquiry into the mechanisms that influence people within their larger social contexts to manage one or multiple conditions over the lifecycle. Long-term goals are to increase knowledge of the individual and group processes that inform thought and behaviors that reinforce health and optimal wellbeing to enhance overall human health, reduce illness and disability, and lengthen life.

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year.

7. Improvement of Animal Models for Stem Cell-Based Regenerative Medicine

Letter of Intent due date: Usually 30 days prior to the application due date

Hyperlink: [\(PAR-16-094\)](#)

Type: R21

[\(PAR-16-093\)](#)

R01

Application Due Date: [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. **R01:** Application budgets are not limited, but need to reflect actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum award period is 4 years for ORIP and 5 years for NIDCR, NIEHS and NIAID. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 – NIH Director’s Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director’s Pioneer Award is not renewable.

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R – International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)